THE DEAL, AT A GLANCE
From the announcementCeribell
01What it doesCeribell develops neuromonitoring technology for critical care.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by Longitude Capital, The Rise FundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedCeribell raised $53M Series C, announced 2021-04-29From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersCeribell’s Series C supports expansion of neuromonitoring technology in critical care settings, with the financing framed around reaching more patients and more…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Ceribell · Financing Record
Explore source-linked visual explanations for Ceribell. Unsupported claims are withheld while source review continues.
Record 2892 · Recorded date: 2021-04-29
Explore company records →